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ABSTRACT
The CATS (FAM64A) protein interacts with CALM (PICALM) and the leukemic 
fusion protein CALM/AF10. CATS is highly expressed in leukemia, lymphoma and tumor 
cell lines and its protein levels strongly correlates with cellular proliferation in both 
malignant and normal cells. In order to obtain further insight into CATS function we 
performed an extensive analysis of CATS expression during differentiation of leukemia 
cell lines. While CATS expression decreased during erythroid, megakaryocytic and 
monocytic differentiation, a markedly increase was observed in the ATRA induced 
granulocytic differentiation. Lentivirus mediated silencing of CATS in U937 cell line 
resulted in somewhat reduced proliferation, altered cell cycle progression and lower 
migratory ability in vitro; however was not sufficient to inhibit tumor growth in 
xenotransplant model. Of note, CATS knockdown resulted in reduced clonogenicity of 
CATS-silenced cells and reduced expression of the self-renewal gene, GLI-1. Moreover, 
retroviral mediated overexpression of the murine Cats in primary bone marrow cells 
lead to decreased colony formation. Although our in vitro data suggests that CATS 
play a role in cellular processes important for tumorigenesis, such as cell cycle control 
and clonogenicity, these effects were not observed in vivo.
INTRODUCTION
The t(10;11)(p13;q14) translocation leads to the 
fusion of the CALM (PICALM) and AF10 genes [1]. 
CALM/AF10 fusions are observed in acute myeloid 
leukemia (AML), acute lymphoblastic leukemia (ALL) 
and in lymphoma [2–5], being very frequent in gamma/
delta lineage T-acute lymphoblastic leukemias [6–8].
The expression of CALM/AF10 leads to the 
development of leukemia in murine bone marrow 
transplantation and transgenic models [9–12], and 
increasing evidence suggests that CALM/AF10 exerts its 
leukemogenic potential through transcriptional deregulation 
of target genes, including the HOXA gene cluster, therefore 
interfering with normal hematopoietic differentiation [9, 
13–15], through increased genomic instability by reducing 
global histone H3K79 methylation [16, 17] and through 
a novel proposed mechanism mediated by the CRM1-
dependent nuclear export pathway [18]. Identification 
of several CALM/AF10 interacting proteins (e.g. CATS 
(FAM64A), DOTL1, IKAROS, FHL2), has shed light 
on the molecular mechanism relevant for CALM/AF10-
mediated leukemogenesis and the possible involvement of 
these proteins in malignant transformation [15, 19–22].
CATS (FAM64A; Gene ID: 54478) was initially 
identified as a CALM interacting partner [19]. The 
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findings that expression of CATS (FAM64A) markedly 
increased the nuclear localization of CALM/AF10 [19] 
and that the murine Cats (Fam64A) transcripts were 
up-regulated in hematopoietic cells (B220+ lymphoid 
cells) transformed by CALM/AF10 in comparison to 
the same subpopulation from non-leukemic mice [10, 
23], suggested that CATS (FAM64A) may play a role 
in CALM/AF10-mediated transformation. In agreement 
with that, CATS (FAM64A) functions as a transcriptional 
repressor [19] capable of antagonizing the transactivation 
activity of the leukemic fusion protein CALM/AF10 in a 
GAL4-based transactivation assay [24]. However, whether 
CATS (FAM64A) contributes to leukemogenesis remains 
to be determined.
In normal adult tissue, CATS (FAM64A) is 
predominantly expressed in the lymphoid compartment, 
whereas it is highly expressed in leukemia, lymphoma and 
tumor cell lines. The protein level of CATS (FAM64A) 
strongly correlates with cellular proliferation in both 
normal and malignant cells [23].
Zhao and co-workers reported that CATS 
(FAM64A) (referred to as RCS1 in their study), is a 
mitotic regulator that controls the metaphase-to-anaphase 
transition [25]. Additional roles for CATS as a neuronal 
protein that is co-expressed and interacts with the cellular 
prion protein (PrPC) have also been proposed [26, 27]. 
Most recently, CATS (FAM64A) was found among the 
three most upregulated genes, whose high expression is 
associated with poor prognosis of more aggressive triple-
negative breast cancer (TNBC) [28].
In order to gain further insight into CATS 
function we performed an extensive analysis of CATS 
expression during differentiation of leukemia cell lines 
and investigated the effect of CATS silencing in the 
CALM/AF10-positive U937 leukemia cell line as well 
as the effect of Cats overexpression in murine primary 
bone marrow cells. Here we show that changes in CATS 
expression affect cell proliferation, cell cycle control and 
clonogenicity of hematopoietic cells.
RESULTS
CATS expression decreases during induced 
differentiation of leukemia cell lines
We first investigated CATS gene and protein 
expression during induced differentiation of leukemia cell 
lines into erythrocytes, megakaryocytes, monocytes and 
granulocytes (Figure 1 and Supplementary Figure S1). 
CATS expression decreased during erythroid (by 60%), 
megakaryocytic (by 43%) and monocytic (by 65% at day 
2, and by 96% at day 4) differentiation (Figure 1A-1C). 
However, CATS expression increased by 2 fold during 
granulocytic differentiation of both NB4 (at day 4) and 
U937 cells (at day 2) (Figure 1D). At day 4 of U937 
granulocytic differentiation, CATS expression returned 
to its initial level. Expression of CATS protein followed 
the same pattern as its transcript levels (Figure 1D, lower 
panels).
CATS knockdown reduces cell proliferation of 
the U937 cell line in vitro
U937 cells were transduced with lentiviral particles 
expressing a pool of multiple shRNAs for silencing CATS. 
This approach provides a selective reduction of off-target 
effects since the pool silence the intended target but have 
unique off-target signatures [29]. CATS silencing was 
efficiently achieved at both mRNA and protein levels in 
shCATS transduced cells when compared to shControl 
cells (Supplementary Figure S2A).
Cell number decreased by approximately 20% 
upon CATS depletion at two different time points: 24h 
(Figure 2A) and 48h (Supplementary Figure S3A), 
as assessed by MTT. No difference in apoptosis was 
encountered (Supplementary Figure S3B), leading us 
to believe the difference in viability was due to reduced 
cell proliferation. Accordingly, Ki-67 analysis revealed 
reduced proliferation of CATS silenced cells by 13% 
(Figure 2B). As shown by cell cycle analysis, a lower 
percentage (12% lower) of cells in the S phase of the 
cell cycle was observed in shCATS cells in comparison 
to shControl cells (Figure 2C). These results indicate 
a reduced proliferation of U937 cells upon CATS 
depletion. Alteration in the cell cycle control was further 
demonstrated by decreased expression of CYCLIN 
A, E and B1 in shCATS cell lysates, as demonstrated 
by Western blotting. Levels of CYCLIN D1 remained 
unaltered in CATS knockdown cells when compared to 
control cells (Figure 2D).
CATS knockdown does not interfere with growth 
of U937 cells in a xenotransplant model
A xenotransplant model was used to assess whether 
CATS depletion would inhibit tumor growth in vivo. No 
difference was observed in volume or weight of shCATS 
and shControl tumors after 12 days of tumor growth 
(Figure 3). CATS knockdown was confirmed on excised 
tumors samples (Supplementary Figure S4).
CATS knockdown does not alter apoptosis of the 
U937 cells
Recently, we identified CATS interaction with 
proteins involved in apoptotic response (unplublished 
data), therefore we wanted to investigate whether CATS 
plays a role in apoptosis. shCATS and shControl cells were 
induced to cell death upon UV irradiation exposition and 
assessed for annexin-V/PI staining. No difference in the 
percentage of viable versus apoptotic cells was observed 
(Figure 4).
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CATS depletion decreases migration of U937 
cells
We performed a transwell chemotaxis assay in order 
to investigate whether CATS contributes to cell migration. 
For that purpose we analyzed shCATS and shControl cell 
migration towards three different chemotatic stimuli: FBS 
(Fetal Bovine Serum), CXCL12 and FBS with CXCL12. 
Approximately 20% fewer shCATS cells than shControl 
cells migrated towards 10% FBS and 10% FBS with 
CXCL12, whereas migration towards CXCL12 was 
unaltered (Figure 5A). Cell migration towards 0.5% BSA 
(used as a control for the experiment) was low and equal 
for both shControl and shCATS.
Next, we investigated expression of proteins 
involved in microtubule dynamics and known to control 
cell migration. Western blot analysis revealed decreased 
expression of α-TUBULIN, and STATHMIN1, as well as 
reduced overall α-TUBULIN acetylation and STATHMIN1 
phosphorylation on residues Ser16 and Ser38 (Figure 5B).
CATS knockdown reduces clonogenicity of U937 
cell line
We employed a colony formation assay to assess 
the clonogenic potential of the CATS depleted U937 cells 
on semisolid medium in the absence of growth factors. 
Figure 1: CATS expression during induced differentiation of leukemia cell lines. Relative CATS expression at days 2 and/or 4 
of differentiation. Upper panels: CATS mRNA levels normalized by HPRT. Lower panels: Representative Western blots of total cell extracts. 
Membrane was blotted against anti-CATS 2C4 and anti-GAPDH, used as a loading control. A. HE + HU induced erythroid differentiation 
of KU812 cells. Results are shown as mean ± SD of three independent experiments. B. PMA induced megakaryocytic differentiation of 
K562 cells. Results are shown as mean ± SD of three independent experiments. C. PMA induced monocytic differentiation of U937 cells. 
Results are shown as mean ± SD of four independent experiments. D. ATRA induced granulocytic differentiation of NB4 (left panel) and 
U937 cells (right panel). Results are shown as mean ± SD of six and four independent experiments, respectively. *p<0.05; **p<0.01 and 
***p<0.001, Student’s t test.
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Figure 2: CATS knockdown reduces proliferation of U937 cells in vitro. Cell proliferation was determined A. by MTT assay 
after 24h of normal culture conditions. Results are shown as mean ± SD of three independent sixplicates experiments. B. Ki-67 mean of 
fluorescence intensity (M.F.I.) determined by flow cytometry after 24h incubation of shCATS and normalized by shControl cells. Results 
are shown as mean ± SD of three independent experiments. C. Percentage of cells on different cell cycle phases determined by flow 
cytometry. Results are shown as mean ± SD of three independent triplicate experiments. D. Western blot analysis of shControl and shCATS 
total cell extracts. Membrane was blotted against anti-CYCLIN A, anti-CYCLIN E, anti-CYCLIN B1, anti-CYCLIN D1, and anti-ACTIN 
or anti-GAPDH, as a control for equal sample loading. The bar graphs represent densitometric analysis of blots relative to control set as 
100% (UN-SCAN-IT software). *p<0.05; **p<0.01, ***p< 0.001, Student’s t test.
Figure 3: CATS knockdown do not interfere with tumor growth in vivo. A. Tumors formed after inoculation of 1 x 107 U937 
shCATS or shControl cells subcutaneously into NOD/SCID mice and excised after 12 days of growth. B. Tumors volume. C. Tumors 
weight.
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Figure 4: CATS knockdown does not alter cell death rate upon UV irradiation. Apoptosis was determined by staining cells 
with Annexin V and PI, followed by flow cytometry analysis. Cells were submitted to UV irradiation (40 J/m2) and collected at the indicated 
time points (0, 3, 6, 9, and 12 hours). The data represents one experiment.
Figure 5: CATS knockdown reduced U937 cell migration towards serum containing media. Migration was evaluated by 
counting the number of cells that passed through the 8μm pore-sized transwell plates and were present in the lower compartment after 24h 
exposure to the chemotatic stimuli. A. Migration towards 0.5% BSA (used as a control), 10% FBS, CXCL12 and 10% FBS + CXCL12 
containing media. The bars represent the number of migrating cells normalized by the input, expressed as percentage. Results are shown 
as mean ± SD of at least three independent duplicate experiments. B. Western blot analysis of shControl and shCATS total cell extracts. 
Membrane was blotted against anti-Ac-α-TUBULIN, anti-α-TUBULIN, anti-SIVA and anti-ACTIN, used as a control for equal sample 
loading (upper panel) and against anti-STMN1 (Ser16), anti-STMN1 (Ser38), anti-STMN1 and anti-ACTIN, used as a control for equal 
sample loading (lower panel). The bar graphs represent densitometric analysis of blots relative to control set as 100% (UN-SCAN-IT 
software). *p<0.05, Student’s t test.
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A significant decrease of 66% in colony number was 
observed for shCATS transduced U937 cells compared to 
the shControl transduced cells (Figure 6A).
In order to investigate a possible mechanism involved 
in the reduced ability of CATS depleted cells to form colonies, 
we analyzed the expression of the self-renewal related genes 
NANOG [30, 31], BMI-1 [32] and GLI-1 [33] in the shCATS 
and shControl cells. Interestingly, while expression of 
NANOG and BMI-1 were not altered, a reduction of GLI-1 
expression ranging between 18% and 75% was observed in 
CATS depleted U937 cells (Figure 6B).
Since CATS interacts with the CALM/AF10 fusion 
protein which is present in the U937 cells, we sought 
to investigated whether CATS depletion in U937 cells 
would affect the expression of the CALM/AF10-leukemia 
deregulated genes HOXA5, HOXA7, HOXA9, HOXA10, 
HOXA11 and MEIS1. Expression of HOXA7, HOXA9, 
HOXA10, HOXA11, and MEIS1 genes were unaffected 
in U937 upon CATS depletion. Although not statistically 
significant, a tendency towards increased HOXA5 
expression was consistently observed in different samples 
of CATS-depleted U937 cells (Figure 6B). In CALM/
AF10 leukemia, HOXA5 overexpression results from 
CALM/AF10 recruitment of hDOT1L and local H3K79 
hypermethylation at the HOXA5 locus [15], whereas a 
global reduction of this epigenetic marker also occurs 
[16]. We analyzed global H3K79 methylation in shCATS 
transduced cells and shControl cells by Western blotting. 
The global H3K79 methylation levels in U937 cells were 
not affected by CATS depletion (Supplementary Figure S5).
Cats overexpression reduces clonogenicity of 
mice primary bone marrow cells
In order to investigate a possible role of Cats in the 
clonogenicity and/or differentiation potential of primary 
bone marrow cells, we retrovirally transduced murine 
progenitor cells to overexpress Cats (Supplementary 
Figure S2B) and performed colony forming cell assays. 
Hematopoietic progenitors overexpressing Cats (MIG-
HA-Cats) formed considerably fewer GM (granulocytes 
and monocytes), BFU-E (erythrocytes) and GEMM 
(progenitors) colonies (60%, 76% and 67%, respectively) 
when compared to cells expressing MIG only (Figure 7A). 
Transduced cells expressing Cats showed a 45% decrease 
in the total number of colony forming units compared to 
control (MIG only) (Figure 7B) and formed 67% fewer 
secondary GM colonies than controls (Figure 7C).
DISCUSSION
To explore the possibility that CATS might 
play a role in leukemogenesis, we performed an 
extensive analysis of CATS expression during induced 
differentiation of leukemia cell lines and functional 
characterization of CATS in the CALM/AF10-positive 
U937 leukemia cells.
Expression analysis on leukemic cell lines showed 
that CATS expression drastically decreased when the 
cells ceased to proliferate upon exposure to a variety of 
differentiation agents. Since we have previously shown 
that CATS is a marker for proliferation, the reduction 
of its expression during the cellular differentiations was 
expected.
However, differently from what was observed for 
erythroid, megakaryocytic and monocytic differentiation, 
granulocytic differentiation resulted in a significant 
increase in CATS expression. CATS upregulation was 
not dependent on the cell line, as it was observed for both 
U937 and NB4 ATRA-treated cells, but not for U937 
PMA-treated cells (monocytic maturation). These results 
suggest that CATS may perhaps play a role in granulocytic 
Figure 6: CATS knockdown reduces colony formation and GLI-1 mRNA expression in U937 cells. A. Colony formation 
assay. Colonies containing viable cells were stained with MTT after 8 days of culture. Images of representative culturing plates are shown. 
The bars represent the number of colonies formed normalized by the control and expressed as percentage. Results are shown as mean ± 
SD of six independent triplicates experiments. B. Relative expression of the self-renewal regulators (NANOG, BMI-1 and GLI-1) and the 
CALM/AF10-leukemia deregulated genes (HOXA5, HOXA7, HOXA9, HOXA10, HOXA11 and MEIS1) in shCATS and shControl cells. 
Results are shown as mean ± SD of at least three independent triplicates experiments. Expression levels of mRNA were normalized by 
HPRT. *p<0.05; **p<0.01, Student’s t test.
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differentiation or could be an ATRA responsive gene. 
Further studies will be necessary to address a possible role 
of CATS in granulocytic differentiation.
Using a lentivirus-mediated shRNA knockdown, 
we demonstrated that CATS silencing reduced cell 
proliferation and lowered the percentage of cells in the 
S-phase of the cell cycle. The inhibitory effect of CATS 
silencing on proliferation was discrete; nevertheless the 
data clearly demonstrates an altered control of cell cycle 
progression, attested by diminished expression of the cell 
cycle regulators CYCLIN A, CYCLIN E and CYCLIN B1, 
responsible for cell entry and progression in the S-phase 
and mitosis, respectively [34]. These results are consistent 
with the described accumulation of CATS protein in S, 
G2 and G2/M phases of the cell cycle and its suggested 
function in these phases [23, 25].
The reduced proliferation in vitro could not be 
documented in vivo, since growth of xenografts from 
U937 cells did not show any significant difference in 
tumor growth depending on the presence or absence of 
CATS. Therefore, CATS silencing was not sufficient to 
hinder tumor growth in this model.
In a previous study we identified KIS and SIVA1 as 
CATS interacting proteins ([24] and data not published). 
These proteins were recently reported to negatively 
regulate STATHMIN and consequently impair cell 
migration through altered microtubule dynamics [35, 36]. 
The interaction between CATS and the two regulators of 
STATHMIN prompted us to investigate whether CATS 
contribute to cellular migration. CATS silencing indeed 
resulted in less migration. Notably, STATHMIN and 
α-TUBULIN expression were downregulated in CATS 
silenced cells. The reduced protein expression was 
accompanied by lower levels of acetylated α-TUBULIN, a 
posttranslational modification only present on microtubule 
polymers (for review [37]) and phosphorylated Ser16 
and Ser38 of STATHMIN, target residues for the CATS 
interacting proteins SIVA1 and KIS, respectively [24, 
35, 36]. These results suggest that the reduced migratory 
ability of CATS depleted cells are due to interference with 
microtubule dynamics in these cells.
The connection of CATS with microtubule 
dynamics is very intriguing. Of note is the report that 
CATS functions during mitosis as a regulator metaphase-
anaphase transition [25], a time when mitotic spindles 
move chromosomes.
Our data demonstrated that CATS depleted U937 
cells form fewer colonies than control cells, leading to the 
conclusion that CATS may play a role in the clonogenicity 
of the U937 cell line. In an attempt to identify possible 
mechanism through which CATS could exert this function, 
we analyzed expression levels of self-renewal genes. We 
Figure 7: Cats overexpression reduces the number of colony formation and total cell number of primary bone marrow 
progenitor cells. A. Transduced cells were cultured in myeloid-conditioned methylcellulose medium for 8 days after which colonies 
were counted. The bars represent the number of GM (granulocytes and monocytes), BFU-E (erythrocytes) and GEMM (progenitors) 
colonies and B. the total number of cells. C. Cells were replated in the same concentration and further cultured for 10 days, allowing 
secondary colony formation. The bars indicate the number of secondary GM colonies. Results are shown as mean ± SD of three independent 
experiments. *p<0.05; **p<0.01, Student’s t test.
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showed that GLI-1, a positive effector of the Hedgehog 
(Hh) signaling pathway [38], was significantly reduced in 
CATS depleted cells. Recently, Wellbrock and colleagues 
demonstrated GLI1 expression as negative prognostic 
factor in AML. In that report, the authors showed that 
shRNA-mediated GLI1 targeted inhibition ranged from 
45% and 69% caused antileukemic effects, resulted 
in a significantly elevated induction of apoptosis and 
significantly reduced proliferation and colony formation in 
all three AML cell lines analyzed [39]. Thus, our findings 
indicate that the GLI1 downregulation observed in CATS 
depleted U937 cells might be functionally relevant, and 
the impairment of this self-renewal pathway could be 
involved in the reduced colony forming ability of the 
CATS depleted cells.
Interestingly, Cats overexpression in murine 
primary bone marrow cells also lead to a decreased ability 
to form different types of colonies and reduced total cell 
number in colony forming cell assays. Taken together, 
these results suggest that any disturbance in the optimal 
expression level of CATS protein might have an impact 
on cell proliferation and clonogenicity.
Interestingly, in a very recent work using single cell 
RNA-Seq analysis of individual hematopoietic stem cells 
(HSCs) Cats (Fam64a) was found to be highly expressed 
in the HSC population primed for proliferation. Single-cell 
colony forming assays confirmed the high proliferation 
and differentiation potential of the Cats-expressing HSC 
population [40].
We have previously hypothesized that through 
its interaction with CALM CATS could play a role in 
CALM/AF10-mediated leukemogenesis [19]. Therefore, 
we analyzed the expression of the HOXA gene cluster, its 
co-factor MEIS1 and BMI1, all known to be deregulated 
in CALM/AF10-positive leukemias [9, 13–15]. We 
observed a tendency of HOXA5 upregulation in CATS 
depleted U937 cells compared to control cells. In CALM/
AF10 leukemia, HOXA5 overexpression results from 
hDOTL1-dependent retention of CALM/AF10 in the 
nucleus and local H3K79 hypermethylation at the HOXA5 
locus [15]. Just like hDOTL1, CATS is able of markedly 
increase the nuclear localization of the CALM/AF10 
fusion protein [19]. Thus, it is tempting to speculate that 
CATS and hDOT1L compete for CALM/AF10 interaction, 
and upon CATS depletion, more hDOT1L is recruited to 
methylate the HOXA5 locus. In addition to local H3K79 
hypermethylation at the HOXA5 locus, CALM/AF10-
positive leukemia is characterized by a global reduction of 
the H3K79 epigenetic mark [16]. However, global H3K79 
methylation did not change upon CATS depletion in U937 
cells. Additional, more locus specific analysis of H3K79 
methylation status after CATS depletion are now required.
Here we targeted CATS in a CALM/AF10 positive 
leukemia cell line and revealed some features of its 
function yet we should bear in mind the limitations of 
using this only cell line in the study. Therefore we can 
neither assume that our findings are restricted to U937 nor 
dependent on CALM/AF10. Although we have some in 
vitro evidences supporting the possible role of CATS in 
CALM/AF10-mediated leukemogenesis (demonstrated 
here and in previous publications [19, 23, 24]), the present 
study does not provide evidence for a role of CATS in in 
vivo CALM-AF10 leukemia.
Nevertheless our functional analysis demonstrates 
that CATS plays a role in cellular processes involved 
in tumorigenesis, such as cell cycle control, migration, 
clonogenicity and possibly self-renewal. Hence, further 
support the notion that disruption of CATS function might 
contribute to tumorigenesis.
MATERIALS AND METHODS
Leukemia cell lines
Leukemia cell lines U937, K562, NB4 and KU812, 
obtained from the American Type Culture Collection 
(ATCC, Manassas, USA) or the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany) were grown according to the suppliers’ 
recommendations and used for cell differentiation, RNA 
and protein extraction, and virus transduction. All cell 
lines were tested and authenticated by STR matching 
analysis using the PowerPlex® 16 HS system (Promega, 
Madison, WI, USA) and the ABI 3500 Sequence Detector 
System (Applied Biosystems, Foster City, CA, USA). 
Additionally, in U937 CALM/AF10 expression was 
confirmed by RT-PCR (data not shown).
Differentiation of cell lines
RNA and protein samples of KU812, K562 and NB4 
leukemia cells induced to differentiate were obtained from 
previous study [41] and CATS expression was assessed in 
the Hemin and Hydroxyurea (HE-HU)-induced erythroid 
differentiation of KU812, the phorbol-13 myristate-12 
acetate (PMA)-induced megakaryocytic differentiation 
of K562 and the all-trans retinoic acid (ATRA)-induced 
granulocytic differentiation of NB4 cells.
U937 cells were induced to differentiate for 2 and 4 
days into monocytes and granulocytes with PMA (20 nM) 
and ATRA (10-6 M) treatment, respectively. Differentiation 
was monitored by flow cytometry for positive staining of 
the cell surface markers CD11b, CD14 and CD15 and by 
qPCR for transcript levels of CD15 and GCSFR. Cells 
were collected for morphology analysis and for RNA and 
protein extraction (Supplementary Figure S1).
Quantitative PCR
Total RNA was isolated using the RNeasy® Mini or 
Micro Kit (Qiagen, Hilden, Germany). DNAse I treated 
RNA was reverse transcribed with oligo dT primers and 
RevertAid™ First Strand cDNA Synthesis Kit (MBI 
Fermentas, St. Leon-Rot, Germany). Reactions were 
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carried out with Maxima SYBR Green qPCR master mix, 
according to the manufacture’s protocol (MBI Fermentas, 
St. Leon-Rot, Germany). The plates were run and analyzed 
by Mastercycler® ep realplex 4 System (Eppendorf, 
Hamburg, Germany). Primer sequences are available upon 
request. HPRT and GAPDH were used as endogenous 
control and relative gene expression was calculated using 
the 2-ΔΔCT equation [42].
Immunobloting
Cellular lysates were electrophoresed on 10-12% 
SDS-PAGE and transferred to nitrocellulose membrane 
(HybondTM ECLTM, GE Healthcare, Buckinghamshire, 
UK). The membranes were blocked and probed with 
specific antibody, followed by detection with fluorescently 
labeled secondary antibodies. Membranes were visualized 
on Alliance 2.7 (UVItec, Cambridge, England). 
Primary antibodies were purchased from Santa Cruz 
Biotechnologies, unless otherwise specified: anti-ACTIN 
(I-19; sc-1616) (1:2000), anti-GAPDH (6C5; sc-32233) 
(1:4000), anti-CYCLIN E (E-4; sc-377100) (1:1000), 
anti-CYCLIN B1 (D-11; sc-7393) (1:1000), anti-CYCLIN 
D1 (A-12; sc-8396) (1:1000), anti-CYCLIN A (H-3; sc-
271645) (1:2000), anti-α-TUBULIN (B-7; sc-5286) 
(1:2000), anti-SIVA (C-20; sc-7436) (1:1000), anti-pOP18 
S16R (sc-12948) (1:2000), anti-pOP18 S38 (sc-101810) 
(1:1000), anti-OP18 (E-3; sc-55531) (1:2000), anti-H3 (C-
16; sc-8654) (1:1000). Anti-H3K79 (ab3594) (1:1000) and 
anti-ACETYL-α-TUBULIN (6-11B-1; ab24610) (1:2000) 
were purchased from Abcam, Cambridge, England 
and anti-CATS 2C4 (1:250) was previously described 
[23]. Secondary antibodies were purchased from Life 
Technologies (Carlsbad, CA, USA): anti-mouse (1:5000), 
anti-rat (1:2000), anti-rabbit (1:10000) and anti-goat 
(1:4000). Quantitative analyses of the optical intensities 
protein bands were determined with UN-SCAN-IT gel 6.1 
software (Silk Scientific, Inc., USA) and normalized by 
control protein.
Transduction of U937 cells
U937 cells (American Type Culture Collection 
(ATCC, Manassas, U.S.A) were transduced with lentivirus 
particles expressing a pool of two short hairpin RNAs 
(shRNA) targeting the CATS sequence (FAM64A sc-
93656-V; Santa Cruz Biotechnologies, CA, USA; siRNA 
target sequences GCUUCAUACUCAAGGAUGUtt and 
GAAGUGCUAGCAUCAGAUAtt) or nonspecific control 
target (sc-108080), named shCATS and shControl cells, 
respectively. Briefly, 2 x 105 cells were transduced by 
spinoculation at multiplicity of infection (MOI) equal to 
1 and stable polyclonal shCATS and shControl cell lines 
were generated after 15 days selection with puromycin (10 
μg/ml).
Proliferation assays
For MTT assay cells were seeded in 96-well plates 
at density of 2.5 x 104 cells/well. After 24 or 48 hours of 
incubation under normal culture condition, 10 μl of a 5 
mg/ml solution of MTT was added per well and incubated 
for 4 hours. Reaction was stopped by adding 100 μl of 
0.1N HCl/isopropanol and proliferation evaluated by 
measuring the absorbance at 570 nm with an automated 
plate reader.
Cell proliferation was further assessed by Ki-67 
staining. ShCATS and control cells were stained with 
Ki-67 antibody according to manufacturer’s instructions 
(Ki-67 PerCP-Cy5.5 clone B56; BD Bioscience, San Jose, 
CA, USA). The mean of fluorescence intensity (M.F.I) was 
obtained by FACS analysis using a FACSCalibur (Becton 
Dickinson, San Jose, CA, USA) and FlowJo software. IgG 
isotype was used as negative control for each condition 
and ten thousand events were acquired for each sample.
Cell cycle analysis
2.5 x 105 cells were fixed in 70% ethanol for 30 
min on ice, washed with PBS and stained with 20 μg/
ml propidium iodide (PI) containing 10 μg/ml RNAse A 
for 30 min at room temperature (RT). Cell cycle analysis 
was performed using FACSCalibur (Becton-Dickinson, 
California, USA) and Modfit (Verify Software House Inc., 
USA).
Apoptosis assays
For apoptosis evaluation, cells seeded in 12-well 
plates were treated with UV irradiation (40 J/m2) and 
collected at 0, 3, 6, 9 and 12 hours after UV exposure. At 
the indicated time points, cells were washed with ice-cold 
PBS and stained with annexin V and PI (BD Biosciences 
Pharmingen, California, USA) for 15 minutes at RT. 
Apoptosis analysis was performed using FACSCalibur 
(Becton-Dickinson) and FACSDiva software (BD 
Biosciences Pharmingen). Ten thousand events were 
acquired for each sample.
Xenograft model of tumor growth in NOD/SCID 
mice
For the xenograft tumor model, 1 x 107 U937 
shCATS or shControl transduced cells were implanted into 
the dorsal sub cutis of 8-12 week-old female non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) 
mice. Tumors grew locally for 12 days, then they were 
excised, measured and weighted. Tumor measurements 
were converted to tumor volume (V) by the formula (V 
= W2 x L x 0.52), where W and L stands for smaller and 
larger diameters, respectively. RNA was extracted from 
tumors samples.
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Migration assay
Migration assays were performed in 12-well 8μm 
pore-sized transwell plates (Costar, Corning, NY, USA). 
Cells were seeded above the filters at a density of 1 x 
105 cells/well. The lower compartment was filled with 
the following media: 10% FBS/0.5% BSA; 200 ng/mL 
CXCL12/0.5% BSA (PeproTech, Rocky Hill, NJ, USA); 
10% FBS/200 ng/mL CXCL12/0.5% BSA and 0.5% BSA 
was used as negative control. After 24 hours, the number 
of cells which migrated through the filter and reached the 
lower compartment was counted. Values were expressed 
as percentage of the input (cells applied directly to the 
lower compartment) set as 100%.
Colony forming assay
shControl and shCATS transduced U937 cells were 
plated in semisolid medium depleted of any growth factors 
(5 x 102 cell/ml; MethoCult 4230; StemCell Technologies 
Inc., Vancouver, Canada). Colonies were detected after 
8 days of culture by adding 200 μl of a 5 mg/ml MTT 
solution and scored by Image J quantification software 
(NIH, Bethesda, Maryland, USA).
Construction of retroviral vector and virus 
production
Murine Cats hemagglutinin (HA)-epitope tagged 
cDNA was generated by PCR and subcloned into the 
multiple cloning site of the modified murine stem cell 
virus vector (MIG), upstream of the internal ribosomal 
entry site (IRES) and enhanced GFP (EGFP) gene (MIG-
HA-Cats). The MIG vector carrying only the IRES-EGFP 
cassette was used as a control.
Production of high-titer helper-free recombinant 
retrovirus was carried out following standard procedures 
[43] by using the ecotropic 293-Phoenix cell line and 
the packing cell line GP+E86 [44]. Briefly, 293-Phoenix 
cells were first transfected with the MIG or MIG-HA-
Cats plasmids. Supernatant was used to infect the GP+E86 
cells, which were sorted based on GFP expression. 
Single cell culture was carried out in order to obtain 
monoclonal populations of GP+E86-MIG or MIG-HA-
Cats viral producer cells. The viral titre was determined 
by transducing NIH3T3 cells.
Retroviral transduction of primary bone 
marrow cells
Primary bone marrow cells were obtained from 
8 to 12-week-old C57BL/6 mice pretreated with 
5-fluorouracil for 5 days. Total bone marrow was 
harvested from femurs and cultured in DMEM, 20% 
FBS (Gibco by Life Technologies, Carlsbad, CA, USA) 
and cytokines (100 ng/mL stem cell factor (SCF), 10 
ng/mL interleukin 6 (IL6) and 6 ng/ml interleukin 3 
(IL3)) for 48 hours. For retrovirus transduction, 5 x 106 
cells were cocultured with 1.2 x 106 virus-producing 
GP+E86 cells (GP+E86-MIG and -MIG-HA-Cats) 
in the presence of cytokines and protamine sulfate 
(5 μg/mL) (Sigma-Aldrich, St. Louis, MO, USA). 
The transduction was stopped by removing the bone 
marrow cells from the GP+E86 cells and culturing them 
in afore mentioned media for another 48 hours to allow 
for GFP expression. Retrovirally transduced cells were 
sorted based on GFP expression on a FACSAria IIu 
(Becton-Dickinson). Sorted GFP-positive cells were 
further cultured for 48 hours in DMEM, 35% FBS 
plus cytokines and used for colony forming cell (CFC) 
assays and RNA extraction.
Colony forming cell assay
2 x 104 transduced cells were cultured in 1% 
myeloid-conditioned methylcellulose medium (MethoCult 
M3434; StemCell Technologies Inc., Vancouver, Canada) 
for 8 days, after which GM (granulocytes and monocytes), 
BFU-E (erythrocytes) and GEMM (progenitors) colonies 
were counted. The total number of cells was determined; 
cells were replated in the same concentration and cultured 
for an additional 10 days, after which secondary colonies 
were counted.
Animal care
Animal care was conducted in accordance with 
the standard ethical guidelines. Protocols have been 
approved by the local ethical committee “Comissão de 
Ética no Uso de Animais (CEUA)/Unicamp” - Protocol 
n° 3165-1. Parental strain mice were bred and maintained 
at the University of Campinas Central Breeding Center 
(Campinas, SP, Brazil).
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